AR026068A1 - MODIFIED AND PEPTIDOMIMETIC PEPTIDES FOR USE IN IMMUNOTHERAPY. - Google Patents
MODIFIED AND PEPTIDOMIMETIC PEPTIDES FOR USE IN IMMUNOTHERAPY.Info
- Publication number
- AR026068A1 AR026068A1 ARP000105458A ARP000105458A AR026068A1 AR 026068 A1 AR026068 A1 AR 026068A1 AR P000105458 A ARP000105458 A AR P000105458A AR P000105458 A ARP000105458 A AR P000105458A AR 026068 A1 AR026068 A1 AR 026068A1
- Authority
- AR
- Argentina
- Prior art keywords
- amino acids
- formula
- substitution
- ser
- thr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Rehabilitation Therapy (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un péptido modificado derivado de H-Arg-Ser-Phe-Thr-Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-Oh (formula 1) que tiene la formula general Q-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-Z (formula 2). En la formula general 2 A1 a A13 corresponden a los aminoácidos de la formula 1, Q corresponde a H y Z corresponde a OH.Las modificaciones se seleccionan de uno o más de los grupos a, b, o c, consistentes en: a)sustitucion de 1-6 de preferencia 1-4 amino ácidos en A1 a A13 poramino ácidos no naturales obeta amino ácidos, b)sustitucion de uno o más enlaces amida por enlaces amida reducidos o isoesteres de etileno, c)sustitucionesen Q y/o Z y, opcionalmente, d)sustitucion por amino ácidos naturales, hasta un total de 6 modificaciones. Los péptidos pueden usarse para la induccion detolerancia en pacientes que sufren de enfermedades autoinmunes.A modified peptide derived from H-Arg-Ser-Phe-Thr-Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-Oh (formula 1) having the general formula Q-A1-A2-A3 -A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-Z (formula 2). In the general formula 2 A1 to A13 correspond to the amino acids of the formula 1, Q corresponds to H and Z corresponds to OH.The modifications are selected from one or more of the groups a, b, or c, consisting of: a) substitution 1-6 preferably 1-4 amino acids in A1 to A13 poramino unnatural acids obeta amino acids, b) substitution of one or more amide bonds with reduced amide bonds or isosteres of ethylene, c) substitutions in Q and / or Z and , optionally, d) substitution by natural amino acids, up to a total of 6 modifications. Peptides can be used for the induction of detolerance in patients suffering from autoimmune diseases.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99203427 | 1999-10-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR026068A1 true AR026068A1 (en) | 2002-12-26 |
Family
ID=8240756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000105458A AR026068A1 (en) | 1999-10-18 | 2000-10-18 | MODIFIED AND PEPTIDOMIMETIC PEPTIDES FOR USE IN IMMUNOTHERAPY. |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP1226167A1 (en) |
| JP (1) | JP2003512388A (en) |
| KR (1) | KR20020047245A (en) |
| CN (1) | CN1379786A (en) |
| AR (1) | AR026068A1 (en) |
| AU (1) | AU780238B2 (en) |
| BR (1) | BR0014803A (en) |
| CA (1) | CA2386398A1 (en) |
| CO (1) | CO5271650A1 (en) |
| CZ (1) | CZ20021356A3 (en) |
| HK (1) | HK1046693A1 (en) |
| HU (1) | HUP0203504A3 (en) |
| IL (1) | IL148778A0 (en) |
| MX (1) | MXPA02003520A (en) |
| NO (1) | NO20021763L (en) |
| NZ (1) | NZ518256A (en) |
| PE (1) | PE20010692A1 (en) |
| PL (1) | PL354590A1 (en) |
| RU (1) | RU2002113107A (en) |
| SK (1) | SK6842002A3 (en) |
| TR (1) | TR200201036T2 (en) |
| WO (1) | WO2001029081A1 (en) |
| ZA (1) | ZA200202577B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002951212A0 (en) * | 2002-09-04 | 2002-09-19 | Monash University | A method of modulating cellular activity and molecules for use therein |
| US20100240137A1 (en) * | 2006-04-06 | 2010-09-23 | Purdue Research Foundation | Derivatization-enhanced analysis of amino acids and peptides |
| WO2008078190A2 (en) * | 2006-12-21 | 2008-07-03 | Universite De Geneve | Compounds for fluorescence imaging |
| CN101971027A (en) | 2008-01-23 | 2011-02-09 | 海莱乌医院 | Ykl-40 as a general marker for non-specific disease |
| NZ592241A (en) | 2008-09-15 | 2012-11-30 | Herlev Hospital | Ykl-40 as a marker for gastrointestinal cancers |
| JP6798998B2 (en) | 2014-11-07 | 2020-12-09 | キネタ・クロニック・ペイン・リミテッド・ライアビリティ・カンパニーＫｉｎｅｔａ Ｃｈｒｏｎｉｃ Ｐａｉｎ， ＬＬＣ | Modification and use of conotoxin peptides |
| EP3466963A1 (en) * | 2017-10-05 | 2019-04-10 | Suigeneris Farmacosmetics, S.L. | Anticancer peptides and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL115744A (en) * | 1994-10-27 | 2000-07-16 | Akzo Nobel Nv | Peptides comprising a subsequence of human cartilage glycoprotein - 39 |
| IL120561A0 (en) * | 1996-04-24 | 1997-07-13 | Akzo Nobel Nv | Peptides suitable for use in immunosuppressive therapy |
| IL127332A0 (en) * | 1996-06-07 | 1999-09-22 | Zeneca Ltd | Peptide derivatives |
| IL122233A (en) * | 1996-12-06 | 2001-04-30 | Akzo Nobel Nv | Method of preparing cell surface monolonal antibodies and pharmaceutical compositions and diagnostic reagents containing them |
-
2000
- 2000-10-12 AU AU11396/01A patent/AU780238B2/en not_active Ceased
- 2000-10-12 KR KR1020027004940A patent/KR20020047245A/en not_active Application Discontinuation
- 2000-10-12 TR TR2002/01036T patent/TR200201036T2/en unknown
- 2000-10-12 JP JP2001531879A patent/JP2003512388A/en not_active Withdrawn
- 2000-10-12 WO PCT/EP2000/010230 patent/WO2001029081A1/en not_active Application Discontinuation
- 2000-10-12 CA CA002386398A patent/CA2386398A1/en not_active Abandoned
- 2000-10-12 RU RU2002113107/15A patent/RU2002113107A/en not_active Application Discontinuation
- 2000-10-12 EP EP00972790A patent/EP1226167A1/en not_active Withdrawn
- 2000-10-12 HU HU0203504A patent/HUP0203504A3/en unknown
- 2000-10-12 SK SK684-2002A patent/SK6842002A3/en not_active Application Discontinuation
- 2000-10-12 BR BR0014803-2A patent/BR0014803A/en not_active IP Right Cessation
- 2000-10-12 CN CN00814418A patent/CN1379786A/en active Pending
- 2000-10-12 NZ NZ518256A patent/NZ518256A/en unknown
- 2000-10-12 MX MXPA02003520A patent/MXPA02003520A/en unknown
- 2000-10-12 IL IL14877800A patent/IL148778A0/en unknown
- 2000-10-12 PL PL00354590A patent/PL354590A1/en not_active Application Discontinuation
- 2000-10-12 CZ CZ20021356A patent/CZ20021356A3/en unknown
- 2000-10-17 PE PE2000001107A patent/PE20010692A1/en not_active Application Discontinuation
- 2000-10-18 CO CO00079334A patent/CO5271650A1/en not_active Application Discontinuation
- 2000-10-18 AR ARP000105458A patent/AR026068A1/en unknown
-
2002
- 2002-04-02 ZA ZA200202577A patent/ZA200202577B/en unknown
- 2002-04-15 NO NO20021763A patent/NO20021763L/en not_active Application Discontinuation
- 2002-11-13 HK HK02108208.9A patent/HK1046693A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2386398A1 (en) | 2001-04-26 |
| MXPA02003520A (en) | 2002-08-20 |
| KR20020047245A (en) | 2002-06-21 |
| NO20021763D0 (en) | 2002-04-15 |
| NO20021763L (en) | 2002-04-15 |
| IL148778A0 (en) | 2002-09-12 |
| ZA200202577B (en) | 2003-09-23 |
| BR0014803A (en) | 2002-06-11 |
| JP2003512388A (en) | 2003-04-02 |
| AU1139601A (en) | 2001-04-30 |
| CN1379786A (en) | 2002-11-13 |
| AU780238B2 (en) | 2005-03-10 |
| HUP0203504A2 (en) | 2003-04-28 |
| SK6842002A3 (en) | 2002-09-10 |
| CO5271650A1 (en) | 2003-04-30 |
| PE20010692A1 (en) | 2001-07-06 |
| HUP0203504A3 (en) | 2005-03-29 |
| CZ20021356A3 (en) | 2002-07-17 |
| NZ518256A (en) | 2004-01-30 |
| WO2001029081A1 (en) | 2001-04-26 |
| PL354590A1 (en) | 2004-01-26 |
| HK1046693A1 (en) | 2003-01-24 |
| EP1226167A1 (en) | 2002-07-31 |
| TR200201036T2 (en) | 2002-08-21 |
| RU2002113107A (en) | 2004-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2564463T3 (en) | Neisserial antigenic peptides | |
| ES2178000T3 (en) | COMPOSITIONS AND METHODS TO TREAT INFECTIONS USING INDOLICIDINE ANALOGS. | |
| ATE280826T1 (en) | CC CHEMOKINCEPTOR C-C CKR-5, DERIVATIVES THEREOF AND USES | |
| FR20C1016I1 (en) | ||
| DE60045524D1 (en) | A chicken GnRH-II analogous to use in the reduction of tumor cell growth | |
| EA200400241A1 (en) | MULTIMERAL CONTRAST SUBSTANCES BASED ON PEPTIDES ARE DIRECTED TO A TARGET | |
| DE60030450D1 (en) | MUC-1-derived peptides | |
| PE20080339A1 (en) | MODIFIED POLYPEPTIDES OF THE COAGULATION FACTOR IX AND USE OF THE SAME FOR TREATMENT | |
| TR199802534T2 (en) | Leptin (OB Protein) fragmanlar� | |
| ES2174770T1 (en) | PEPTIDES DESIGNED FOR DIAGNOSIS AND TREATMENT OF Rheumatoid ARTHRITIS. | |
| SG162791A1 (en) | Mucin hypersecretion inhibitors based on the structure of mans and methods of use | |
| AR026068A1 (en) | MODIFIED AND PEPTIDOMIMETIC PEPTIDES FOR USE IN IMMUNOTHERAPY. | |
| YU53803A (en) | Peptides and/or proteins and use thereof for the production of a therapeutic and/or prophylactic medicament | |
| DK0491628T3 (en) | Lipopeptides inducing cytotoxic T lymphocytes and their use as vaccines | |
| NZ592340A (en) | A method for making a virus vaccine compising Replikin peptides | |
| DE602004028266D1 (en) | ANGIOGENIC PEPTIDES AND ITS USES | |
| ATE355302T1 (en) | PEPTIDES CONTAINING N-SUBSTITUTED D-AMINO ACIDS FOR PREVENTING BETA STRAND ASSOCIATION | |
| DE69938130D1 (en) | NEW PEPTIDE | |
| TW200505943A (en) | Polypeptide | |
| DK1504036T3 (en) | Toxin-related fragments of antibodies with antimicrobial and antiviral activity | |
| ECSP003720A (en) | MODIFIED AND PEPTIDOMIMETIC PEPTIDES FOR USE IN IMMUNOTHERAPY | |
| ATE25984T1 (en) | PHARMACOLOGICALLY ACTIVE PEPTIDES. | |
| AR004497A1 (en) | AN ANALOGUE CYCLIC HEXAPEPTIDE OF SOMATOSTATINA, PROCEDURE TO PREPARE THEM AND THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THE USE OF SUCH HEXAPEPTIDE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION. | |
| ID27162A (en) | HLA-A2 ANTIGENT TUMOR PEPTIDES LIMITED FROM SART-1 | |
| ATE291587T1 (en) | SOMATOSTATIN ANALOGUES AND THEIR USE IN THE TREATMENT OF CANCER |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |